Global Pharmaceutical Powers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Global Pharmaceutical Powers
Another Asian services provider demonstrates the global nature of pharmaceutical outsourcing.


Pharmaceutical Technology


Admittedly, it is more difficult for Western companies to establish themselves in India and China than for Asian companies to come west due to restrictive regulations governing foreign investment and the challenges of learning to operate in a different culture. But most Western service companies seem to be held back by a severe aversion to risk and an unwillingness to accept near-term losses and uncertainties in return for longterm strategic opportunities. It would be unfortunate if the pharmaceutical services industry's pioneers ceded their future to a band of relative newcomers, but it wouldn't be the first time that happened in the history of business.

CROs on parade

Like all corporations, CROs and CMOs have three principal constituencies: customers, employees, and shareholders. Presentations to customers and employees are usually focused on how the company will help them be successful, but presentations to shareholders are about how the company itself will be successful. As such, shareholder presentations provide a window into company strategies, their executives, and how they view market trends.

The annual JPMorgan Healthcare Conference, held in San Francisco last month, brought together CEOs and CFOs from more than 200 public and private bio/pharmaceutical, medical device, diagnostic, and managed care companies. The CEOs and CFOs addressed some 7000 money managers and dealmakers to explain why they should invest in their companies. The CRO and pharmaceutical supplier sectors were well represented at this year's conference, with more than 15 companies presenting.

Because profit margins and growth prospects drive stock valuations, investors want to know how companies will grow their revenues and profits. The CRO executives, in particular, had a very compelling story: major pharmaceutical companies are embracing outsourcing as part of their efforts to restructure their business models, and those efforts will drive the CRO business for years to come. All noted that the bio/pharmaceutical industry outsources only about 25% of its R&D spending, so they expect to enjoy robust growth simply by taking a piece of the growing share that will be outsourced. The bigger CROs also expect to fuel growth by increasing their market share of outsourced spending (e.g., by building massive preclinical toxicology laboratories or enhancing their ability to conduct large global trials). In their view, the balance of power has shifted from the pharmaceutical companies to the service providers over the past three years.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905,
http://www.pharmsource.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
7%
Provide treatment for patients globally.
7%
All of the above.
43%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here